Yersinia pseudotuberculosis employs a type III secretion system for targeting of several virulence factors directly to the cytosol of eukaryotic cells. This protein translocation mechanism mediates the ability of Yersinia to resist phagocytosis and is required for sustained extracellular bacterial replication. In the present study, the Yersinia outer protein E (YopE) was used as a carrier molecule for type III-dependent secretion and translocation of listeriolysin O (LLO) from Listeria monocytogenes. In comparison to wild-type Yersinia, an attenuated Y. pseudotuberculosis yopK-null mutant strain hypertranslocates chimeric YopE/LLO into the cytosol of macrophages, resulting in enhanced major histocompatibility complex (MHC) class I-restricted antigen presentation of an LLO-derived CD8 T-cell epitope. Remarkably, T-cell activation assays also revealed a superior ability of translocated over secreted LLO to induce MHC class II-restricted antigen presentation. These in vitro observations were confirmed after immunization of mice with a single dose of the yopK-null mutant strain. Animals orally inoculated with recombinant Yersinia expressing translocated chimeric YopE/LLO revealed high numbers of gamma interferon-producing LLO-specific CD4 and CD8 T cells. For the first time, it is shown that cytosolic antigen display mediated by an extracellular bacterial carrier vaccine results in simultaneous CD4 and CD8 T-cell priming, conferring protection against an intracellular pathogen.
The genus Yersinia includes three pathogenic species. In humans, Y. pestis is the causative agent of bubonic plague. Y. pseudotuberculosis and Y. enterocolitica cause a systemic infection similar to plague in rodents, whereas in humans they cause a self-limiting gastrointestinal disease. A 70-to 75-kb virulence plasmid common to these pathogenic Yersinia species encodes a number of secreted proteins designated Yersinia outer proteins (Yops) that are part of a multicomponent secretion system (10) . This secretion system, termed the type III secretion system (TTSS), is used by bacteria to establish a remarkable relationship to eukaryotic cells (24) . When Yersinia species bind to the surface of macrophages, at least six Yops are delivered directly in a type III-dependent fashion into the cytosol of the host cell (32) , mediating the ability to resist phagocytosis (3, 38) and to trigger apoptosis (42) . The consequence of this translocation process is that pathogenic yersiniae survive and proliferate at extracellular sites in the infected host (49) .
Recent progress in the development of bacterial live carrier vaccines has been made by the use of TTSS for heterologous antigen delivery (25, 44, 45, 46) . In vitro studies have described and analyzed in detail the potential of YopE as a carrier molecule for heterologous antigen delivery by Y. enterocolitica (45) . YopE is a translocated GTPase-activating molecule that can down-regulate Rho activity, leading to actin filament disruption and inhibition of phagocytosis by macrophages (4, 39, 40, 56) . The N-terminal 18 amino acids of YopE fused to a large protein fragment of the p60 antigen from the intracellular pathogen Listeria monocytogenes were sufficient for type III-dependent secretion to the extracellular environment of Yersinia-infected target cells (45) . In contrast, fusion of p60 to the N-terminal 138 amino acids of YopE resulted in translocation of the chimeric protein into the cytosol of host cells (45) . T-cell activation assays revealed that the cytosolic delivery of the hybrid protein was a prerequisite to induce a p60-specific major histocompatibility complex (MHC) class I-restricted antigen presentation (45) .
Y. enterocolitica has been already recognized as a potential bacterial live carrier for vaccination purposes. In the mouse model of infection, Sory et al. made use of Y. enterocolitica strains to induce serum antibody responses against the cytoplasmic CRA protein of Trypanosoma cruzi fused to YopE (52) . However, currently there is no information available about the in vivo ability of the Yersinia TTSS to induce MHC class I-and II-restricted immune responses against heterologous antigens. Therefore, the aim of the present study was to investigate whether Yersinia is capable of efficient CD4 and CD8 T-cell priming in orally immunized mice. For this purpose, we used a Y. pseudotuberculosis yopK-null mutant strain as a bacterial carrier vaccine. Previously, this strain was found to be avirulent for orally infected mice (22) . In addition, it has been shown elsewhere that the yopK-null mutant was able to colonize and persist in the Peyer's patches of these mice for up to 10 days, whereas it was unable to colonize the spleen (22) . Further characterization of the yopK-null mutant revealed that this strain showed a dramatic increase in YopE translocation (23) . This indicated that YopK is not a virulence protein per se but rather has a role in the control of translocation of antihost factors such as YopE (23) . The inability of the yopK mutant strain to reach the bloodstream and to cause bacteremia on one hand and the ability to hypertranslocate YopE into eukaryotic cells on the other hand are desirable features of an attenuated bacterial carrier vaccine to be used for type IIImediated MHC class I-restricted heterologous antigen presentation.
In this study, listeriolysin O (LLO) of L. monocytogenes fused to YopE was used as a model antigen. The murine Listeria infection is mainly characterized by the development of a protective CD8 T-cell response (28) . CD4 T cells also respond to L. monocytogenes infection and can confer protective immunity (28) . We demonstrate for the first time that translocation of chimeric YopE/LLO into the cytosol of antigenpresenting cells (APC) by a Y. pseudotuberculosis yopK-null mutant strain results in the induction of a codominant antigenspecific CD4 and CD8 T-cell response in orally vaccinated mice and animal protection against a virulent L. monocytogenes challenge.
(This research was conducted by U. Gerdemann in partial fulfillment of the requirements for a Ph.D. from the Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Ludwig Maximilians University, Munich Germany.)
MATERIALS AND METHODS
Plasmids, bacterial strains, and growth conditions. Escherichia coli 6060 was used as an intermediate host for cloning procedures. Both chimeric proteins used in this study are tagged at their C terminus with an M45 epitope tag (MDRSRDRLPPFETETRIL) that is derived from the E4-6/7 protein of adenovirus (36). Previously described plasmid pHR231 (46) was digested with BamHI and SalI to retrieve a gene fragment encoding LLO /M45. This fragment was cloned into the BamHI and SalI sites of plasmids pCJYE18-G3 and pCJYE138-G3 (26) . The resulting plasmids pHR429 and pHR430 are pACYC184 derivatives (7) . They bear the genetic information for the YopE chaperone SycE and for chimeric YopE 1-18 /LLO 51-363 /M45 or YopE 1-138 / LLO 51-363 /M45, respectively. Plasmid vectors constructed in this study were transformed into wild-type Y. pseudotuberculosis pIB102 (6), the attenuated Y. pseudotuberculosis yopK mutant strain pIB155 (23) , and the attenuated Y. pseudotuberculosis ypkA mutant strain pIB44 (15) by electroporation. Overnight cultures of Y. pseudotuberculosis strains were grown in Luria-Bertani (LB) medium at 27°C. Next day, cultures were diluted and incubated at 37°C for 4 h to allow expression of components and targets of the TTSS encoded by the Yersinia virulence plasmid (45) . When required, the antibiotics kanamycin (30 g/ml) and chloramphenicol (20 g/ml) were added. L. monocytogenes strain sv1/2a EGD (29) was used for challenge experiments in Yersinia-vaccinated mice.
Western blot analysis of secreted and translocated hybrid YopE/LLO proteins in Yersinia-infected P388D 1 cells. The detection of secreted and translocated chimeric YopE/LLO was carried out as described by Collazo and Galán (9) with the following modifications. Briefly, P388D 1 macrophage-like cell monolayers were grown in 100-mm-diameter tissue culture plates in Dulbecco modified Eagle medium supplemented with 5% fetal bovine serum. Cells were infected with Y. pseudotuberculosis strains expressing different hybrid YopE/LLO proteins with a multiplicity of infection (MOI) of 10 in 2.5 ml of Hanks' balanced salt solution (HBSS) at 37°C. Prior to infection, bacterial overnight cultures (LB medium, 27°C) were diluted and incubated at 37°C for 4 h. After infection for 5 h, nonadherent bacteria were removed and cells were washed with HBSS. The infection supernatant was combined with the material from the washes and centrifuged at 8,000 ϫ g for 20 min. The pellet containing nonadherent bacteria was resuspended in 200 l of phosphate-buffered saline (fraction of non-cellassociated bacteria). The supernatant was filtered through a 0.45-m-pore-size syringe filter, and proteins were precipitated by addition of 10% trichloroacetic acid (fraction of bacterium-free infection medium). Infected P388D 1 cells were incubated for 30 min with Dulbecco modified Eagle medium containing 100 g of gentamicin/ml to kill the cell-associated extracellular bacteria. Cells were then treated with 30 g of proteinase K/ml in HBSS for 15 min at 37°C to eliminate cell surface-associated Yops. After proteinase K treatment, 3 ml of chilled HBSS containing 2 mM phenylmethylsulfonyl fluoride was added. Cells detached during the proteinase K treatment and were subsequently collected by low-speed centrifugation (600 ϫ g for 10 min) and lysed in 1 ml of HBSS containing 0.1% Triton X-100 and 1 mM phenylmethylsulfonyl fluoride. Then the cell lysate was centrifuged at 15,000 ϫ g for 10 min. The supernatant was filtered through a 0.45-m-pore-size syringe filter, and proteins were precipitated in the presence of 10% trichloroacetic acid (fraction of Triton X-100-soluble P388D 1 cell lysate containing translocated proteins). Samples were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes as described previously (9) . Hybrid YopE/LLO proteins tagged at their C terminus with an M45 epitope were detected by immunoblot analysis. Western blots were treated with a monoclonal antibody (MAb) directed against M45 (kind gift of P. Hearing, State University of New York, Stony Brook) followed by horseradish peroxidase-labeled anti-mouse antibody. Blots were developed by using a chemiluminescence kit.
Immunofluorescence analysis of hybrid YopE protein translocation. P388D 1 cells were grown on glass coverslips to 60% confluency. One hour before the addition of bacteria, Dulbecco modified Eagle medium was replaced by 500 l of HBSS. Bacteria were grown overnight for 12 h at 27°C in LB medium, diluted 1:20 in fresh medium, and grown for another 4 h under mild aeration to reach an optical density at 600 nm of 0.9. P388D 1 cells were infected with Y. pseudotuberculosis at an MOI of ϳ10 for 30 min or 2 or 5 h at 37°C and 5% CO 2 . Cells were washed three times with HBSS to remove non-cell-associated bacteria and fixed in phosphate-buffered saline-3.7% formaldehyde. Cell-associated extracellular bacteria were stained with an anti-Y. pseudotuberculosis lipopolysaccharide (LPS) polyclonal rabbit antiserum (kind gift of R. Rosqvist, Umeå University, Umeå, Sweden) and a secondary anti-rabbit tetramethylrhodamine isothiocyanate (TRITC) conjugate (1:100 in phosphate-buffered saline-3% bovine serum albumin; Sigma, Deisenhofen, Germany). After permeabilization of P388D 1 cells (3 min in phosphate-buffered saline-0.1% Triton X-100), translocated hybrid YopE/LLO/M45 protein was detected with an anti-M45 MAb and an anti-mouse fluorescein isothiocyanate (FITC) conjugate (1:100 in phosphate-buffered saline-3% bovine serum albumin) (Sigma). Coverslips were mounted on glass slides and analyzed by fluorescence microscopy. Experiments were repeated at least three times.
Mice. Female CB6F1 mice, 6 to 8 weeks old, were purchased from RCC (Füllinsdorf, Switzerland). All mice were kept under specific-pathogen-free conditions (positive-pressure cabinet) and were provided with food and water ad libitum.
Oral immunization of mice with recombinant Yersinia and in vivo protection assay. Groups of 12 mice were immunized either orally with a single dose of 5 ϫ 10 9 CFU of attenuated Y. pseudotuberculosis yopK-null mutant strain pIB155, pIB155(pHR429), or pIB155(pHR430) or intraperitoneally with 5 ϫ 10 3 CFU of L. monocytogenes. Eight weeks after inoculation four mice per group were sacrificed, and spleens were used for further enzyme-linked immunospot (ELI-SPOT) analysis. The remaining eight mice per group were challenged intravenously with 10 3 CFU of log-phase L. monocytogenes strain sv1/2a EGD in 0.2 ml of phosphate-buffered saline. Three days after the challenge, CFU were determined by plating serial dilutions of spleen homogenates on PALCAM Listeria selective agar (Merck, Darmstadt, Germany). Colonies were enumerated after 48 h of incubation. Colony counts were corrected for dilution and averaged to yield CFU per organ. The level of protection was calculated as the log 10 difference of the bacterial counts from immunized mice and naive control mice. Protection assays were repeated twice with similar results.
Bone marrow cultures. Bone marrow-derived macrophages were obtained from bone marrow cultures of CB6F1 mice as described previously (50) and grown in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum and 10 ng of granulocyte-macrophage colony-stimulating factor/ml (R&D Systems, Wiesbaden, Germany). Macrophages were seeded at a density of 10 5 cells per well in 96-well flat-bottomed tissue culture plates and were fed with 100 l of granulocyte-macrophage colony-stimulating factor-supplemented medium every 4 days. Macrophages were used for antigen presentation assays after 12 to 16 days of culture and were treated with 100 U of gamma interferon (IFN-␥; R&D Systems)/ml for 24 h before use. 3 CFU of L. monocytogenes and was repeatedly restimulated with syngeneic mitomycin C-inactivated splenocytes as APC in the presence of 10 Ϫ6 M peptide (50) . Both CD4 and CD8 T cells were grown in ␣-modified Eagle's medium (Invitrogen, Karlsruhe, Germany) supplemented with glutamine, penicillin, streptomycin, 10% fetal bovine serum, 100 U of recombinant murine interleukin 2 (R&D Systems)/ml, and 2 ϫ 10 Ϫ5 M mercaptoethanol. T-cell recognition of infected bone marrow-derived macrophages was measured by the detection of IFN-␥ in culture supernatants as described previously (50) . Briefly, macrophages were infected with Y. pseudotuberculosis in 96-well flat-bottomed microwell plates by 10 min of 200 ϫ g centrifugation. After 2 h at 37°C infected APC were washed twice and culture medium supplemented with 50 g of gentamicin/ml was added. After a further 18 h at 37°C, cells were fixed for 10 min with 1% paraformaldehyde in phosphatebuffered saline, and after thorough washing, 5 ϫ 10 4 T cells were added to each well. The sensitivity of T-cell lines was monitored with APC loaded with graded amounts of the corresponding target peptides. After 12 to 18 h at 37°C, supernatants were harvested and the IFN-␥ concentration was measured by means of an IFN-␥-specific enzyme-linked immunosorbent assay (ELISA) that binds and detects IFN-␥ with a pair of specific MAbs. Results were corrected for dilution of the sample to yield the sample concentration in nanograms per milliliter.
T-cell lines and antigen presentation assay. CD8 T cells against the H-2K
ELISPOT assay. The frequency of T lymphocytes in mice immunized with attenuated Y. pseudotuberculosis was determined with an IFN-␥-specific ELI-SPOT assay as described previously (46) . Assays were performed in nitrocellulose-backed 96-well microtiter plates (Nunc, Wiesbaden, Germany) coated with rat anti-mouse IFN-␥ MAb (RMMG-1; Biosource, Camarillo, Calif.). 
RESULTS

Construction of chimeric YopE/LLO/M45 fusion proteins.
The delivery of YopE by extracellular Yersinia directly to the cytosol of eukaryotic cells has been visualized by confocal microscopy (41) and characterized by the YopE-adenylate cyclase reporter enzyme strategy (53) . Analysis of the secretion and translocation of several chimeric YopE proteins revealed that the required information for YopE secretion and translocation is located in the N terminus of the 23-kDa molecule. The minimal sequence shown to be sufficient for secretion of YopE was found to comprise 11 to 15 residues (47, 54). The minimal domain required for translocation of YopE across the eukaryotic cell membrane was reduced to 50 amino acids comprising the binding site of the YopE-specific chaperone (SycE) which is required for YopE translocation (33) . Recently, we have demonstrated with Salmonella enterica serovar Typhimurium that these well-defined N-terminal secretion and translocation domains of YopE fused to large portions of LLO from L. monocytogenes can be engaged to direct the heterologous antigen to the cytosol of APC (46) . This vaccination strategy resulted in the induction of antigen-specific CD8 T-cell responses in orally vaccinated mice and animal protection against a virulent Listeria challenge (46) .
In this study, we constructed two plasmid vectors. Plasmid pHR429 encodes the N-terminal 18 amino acids of YopE fused to LLO , resulting in a hybrid protein that contains the secretion domain but lacks the translocation domain of YopE (Fig. 1A) . Plasmid pHR430 bears the genetic information for YopE 1-138 /LLO . This hybrid protein contains both the secretion and translocation domains of YopE. To facilitate recognition, both chimeric molecules were tagged at their C terminus with an M45 epitope (Fig. 1A) . Plasmids pHR429 and pHR430 carry also the sycE gene. It has been previously shown by our laboratory that concomitant expression of sycE and hybrid yopE gene fusions from the same plasmid significantly increases the translocation and antigen presentation efficiency of listerial proteins (45, 46) . Transcription of plasmid-borne sycE and gene fusions is mediated by the wild-type yopE/sycE promoters that are both regulated by the Yersinia TTSS.
Hypertranslocation of chimeric YopE/LLO into the cytosol of macrophages by a Y. pseudotuberculosis yopK-null mutant (Fig. 1B) : (i) nonadherent yersiniae that were free from infection medium, (ii) Yersinia-free infection medium, and (iii) Triton X-100-soluble cell lysate containing cytosolic proteins. Figure 1B reveals that pIB155(pHR429) secreted the respective YopE hybrid protein into the infection medium at concentrations indistinguishable from those of pIB102(pHR429). As expected and demonstrated in recent publications (45, 46) , YopE 1-18 /LLO/M45, which lacks the YopE translocation domain, was not found in the cytosol of macrophages infected with pIB102(pHR429) or pIB155(pHR429). In contrast, chimeric YopE 1-138 /LLO/M45 containing the secretion and translocation domains of YopE was readily detected in the cytosol of P388D 1 cells infected with pIB102(pHR430) or pIB155 (pHR430). Interestingly, the yopK-null mutant strain showed increased translocation of chimeric YopE compared to that of wild-type Y. pseudotuberculosis. In fact, enhanced chemiluminescence-Western blot analysis of serial dilutions of the different lysates revealed that P388D 1 cells infected with pIB155 (pHR430) contained about 20 to 25 times more hybrid YopE 1-138 /LLO/M45 protein than did lysates of cells infected with pIB102(pHR430) (data not shown).
To further delineate the difference in the translocation efficiencies of Y. pseudotuberculosis wild type and the isogenic yopK-null mutant strain, P388D 1 cells were infected with pIB102(pHR430) or pIB155(pHR430) for three different periods of time. Macrophages were fixed 30 min or 2 or 5 h after infection and processed for immunofluorescence staining with antibodies directed against M45 and Y. pseudotuberculosis LPS antigen. The left panels of Fig. 2 show typical images of extracellular Yersinia (TRITC signal, red color) and translocated chimeric YopE/LLO (FITC signal, green color) at these three different time points. No fluorescent anti-M45 FITC signal was detected in macrophages 30 min after infection. In contrast, 2 h postinfection hybrid YopE 1-138 /LLO/M45 protein translocated by the yopK-null mutant strain gave a prominent FITC signal whereas no such signal could be detected in samples infected with the wild-type strain pIB102(pHR430). Five hours after infection, translocation of hybrid YopE was visualized by immunofluorescence microscopy in P388D 1 cells infected with either pIB102(pHR430) or pIB155(pHR430). However, macrophages infected with the yopK-null mutant strain gave a much stronger FITC signal than did cells infected with Y. pseudotuberculosis wild type.
Taken together, concordant results from the biochemical fractionation and immunofluorescence staining of Yersinia-infected P388D 1 cells clearly demonstrate that the Y. pseudotuberculosis yopK mutant strain hypertranslocates chimeric YopE/LLO proteins into the cytosol of macrophage-like cells.
Hypertranslocation of chimeric YopE/LLO leads to enhanced antigen-specific MHC class I-restricted antigen presentation. Efficient antigen display is an indispensable requirement for T-cell induction. The strength of antigen presentation generally depends on antigen access to the relative processing compartment, antigen processing efficacy, and antigen abundance (57) . Hypertranslocation of antigen should improve an- (55), and CD8 T cells specific for this epitope transfer protective immunity against L. monocytogenes to naive mice (21) .
We directly compared the efficiencies of Y. pseudotuberculosis wild type and the Y. pseudotuberculosis yopK-null mutant strain expressing chimeric YopE/LLO/M45 in delivering LLO 91-99 to the MHC class I-restricted antigen presentation pathway. Bone marrow macrophages derived from CB6F1 mice were infected with various Yersinia strains and used as APC. The ability of infected cells to present LLO 91-99 to CD8 T cells was assessed in an in vitro antigen presentation assay by measuring secreted IFN-␥ in the culture supernatant (Fig. 3) . Macrophages infected with pIB155(pHR430) hypertranslocating YopE 1-138 /LLO were efficiently recognized by LLO 91-99 -specific T cells, whereas APC infected with wild-type strain pIB102(pHR430) stimulated a much weaker LLO 91-99 -specific T-cell response. As expected, bone marrow macrophages infected with pIB102(pHR429) or pIB155(pHR429) secreting but not translocating chimeric YopE 1-18 /LLO protein were less efficiently recognized by LLO 91-99 -specific T cells or did not induce any measurable level of IFN-␥ secretion, respectively. Thus, efficient antigen presentation and CD8 T-cell stimulation were significantly enhanced in vitro by cytosolic delivery of the hypertranslocated chimeric YopE/LLO protein by the yopK-null mutant strain.
Superior ability of translocated over secreted chimeric YopE/LLO to induce antigen-specific MHC class II-restricted antigen presentation. Currently, there is no information available about the efficacy of MHC class II-restricted antigen presentation of heterologous proteins delivered by the Yersinia TTSS. The effect of Yersinia-mediated secretion, regular translocation, and hypertranslocation of the YopE/LLO fusion protein on MHC class II-restricted antigen presentation was therefore studied with the immunodominant H-2A b -restricted CD4 T-cell epitope LLO [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] (17) . Surprisingly, infection of bone marrow macrophages derived from CB6F1 mice with pIB102(pHR430) or pIB155(pHR430) translocating chimeric YopE/LLO into the host cell cytosol resulted in pronounced stimulation of LLO 190-201 -specific CD4 T cells (Fig. 4) . In contrast, APC infected with pIB102(pHR429) or pIB155 (pHR429) secreting YopE/LLO to the extracellular environment stimulated a significantly weaker antigen-specific CD4 T-cell response.
At an MOI of 10, the amount of YopE 1-138 /LLO/M45 hypertranslocated by pIB155(pHR430) did not result in superior MHC class II-restricted antigen presentation (Fig. 4) compared to the lower amount of chimeric protein delivered by pIB102(pHR430) (Fig. 1B and 2 ). It is conceivable that at this particular MOI the amount of hybrid protein translocated by both recombinant Yersinia strains already reached the level of saturation for sufficient MHC class II antigen presentation. However, at an MOI of 1 the effect of enhanced cytosolic delivery of hybrid YopE/LLO correlated with a more efficient antigen presentation of LLO [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] by APC.
In summary, results from in vitro MHC class I and II antigen presentation assays indicate that cytosolic translocation of LLO leads to MHC class I-restricted and, remarkably, to efficient MHC class II-restricted antigen display. In particular MHC class I antigen presentation can be further enhanced by hypertranslocation of chimeric YopE/LLO. (Fig. 5) . In contrast, in the group of animals immunized with the vaccine strain pIB155 or pIB155(pHR429) secreting YopE 1-18 /LLO the frequency of IFN-␥-producing cells reactive with LLO 190-201 and LLO 91-99 was below the detection limit of the ELISPOT assay. These experiments verify the results obtained from the antigen presentation assays. In accordance with the in vitro observations and as expected, cytosolic delivery of translocated but not of secreted YopE/LLO led to prominent MHC class I-restricted antigen presentation and antigen-specific CD8 T-cell priming. Strikingly, translocation but not secretion of chimeric YopE resulted in efficient LLO-specific CD4 T-cell induction after oral immunization of mice. To increase the available amount of secreted YopE/LLO for exogenous antigen presentation by APC in vivo, we orally applied 5 ϫ 10 9 CFU of pIB155(pHR429) to mice on three consecutive days (data not shown). Even with this immunization strategy, the frequency of LLO 190-201 -specific CD4 T cells was below the detection limit of the ELISPOT assay.
Vaccine-induced protection against listeriosis depends on translocation but not on secretion of chimeric YopE/LLO. Eight weeks after oral immunization with the Y. pseudotuberculosis yopK-null mutant strain expressing hybrid YopE proteins, CB6F1 mice were intravenously challenged with 10 (Fig. 6 ). In contrast, no bacteria were detected in spleens of mice that had received a sublethal intraperitoneal dose of 5 ϫ 10 3 CFU of Listeria 8 weeks before the challenge infection. Mice immunized with pIB155(pHR429) secreting but not translocating LLO showed no significant difference of the bacterial load in spleens ([3.8 Ϯ 3.6] ϫ 10 5 CFU) from mice immunized with the nontransformed yopK-null mutant strain. However, animals orally inoculated with pIB155 (pHR430) translocating LLO revealed a significant reduction of bacterial colonization in their spleens ([1.2 Ϯ 1.5] ϫ 10 2 CFU, P Ͻ 0.05). After single oral immunization, this protection against a primary Listeria infection was presumably mediated by LLO 91-99 -specific CD8 T cells (55) .
DISCUSSION
A variety of attenuated Salmonella, Mycobacterium, and Listeria mutant strains have been reported elsewhere to enable the presentation of heterologous antigens to the immune system of vaccinated mice for proper CD8 T-cell priming (1, 11, 13, 34, 44, 48) . A characteristic feature of these bacterial carrier vaccines is their ability to invade host cells. Thus, their intracellular localization facilitates the delivery of foreign proteins into the endogenous pathway of antigen processing. In contrast to intracellular bacteria, Yersinia species have evolved a strategy to survive and multiply within the lymphoid tissue, predominantly extracellularly (35, 49) . This strategy might be an advantageous feature for a carrier vaccine strain. Extracellular location may help the host's immune system to eliminate the recombinant strain after a decent interval post-oral immunization and thus prevent a chronic colonization.
It was tempting to hypothesize that the attenuated Y. pseudotuberculosis yopK-null mutant strain previously reported to hypertranslocate wild-type YopE has the potential to induce a pronounced antigen-specific CD8 T-cell response after increased cytosolic delivery of YopE/LLO. In this study, in vitro experiments revealed that hypertranslocation of hybrid YopE into the cytosol of APC indeed resulted in a significantly better MHC class I-restricted antigen presentation of LLO 91-99 than did translocation mediated by wild-type Y. pseudotuberculosis. Moreover, single oral application of the yopK-null mutant strain resulted in the induction of a prominent LLO-specific CD8 T-cell response in mice. An important question arises from these in vivo vaccination data. Does an attenuated Y. pseudotuberculosis mutant strain regularly translocating YopE/ LLO induce a comparable frequency of LLO-specific CD8 T cells in orally vaccinated mice as the hypertranslocating Y. pseudotuberculosis yopK-null mutant strain does, or is hypertranslocation of the antigenic fusion protein absolutely required for efficient in vivo T-cell priming? To address this question, we used a Y. pseudotuberculosis ypkA mutant strain (15) for further experiments (data not shown). Previously, it has been demonstrated that the YpkA protein exhibits a Ser/ Thr kinase activity, which is required for the virulence of Y. pseudotuberculosis (15, 16) . Like pIB155, the ypkA mutant strain pIB44 was able to colonize the Peyer's patches of BALB/c mice for several days after oral inoculation but was unable to disseminate into the spleen (16) . A biochemical fractionation of macrophages infected with pIB44(pHR430) or pIB102(pHR430) and additional immunofluorescence microscopy studies revealed that the amount of hybrid YopE/LLO translocated by wild-type Y. pseudotuberculosis was indistinguishable from the amount of chimeric YopE translocated by the isogenic ypkA mutant strain (data not shown). This observation was confirmed by an in vitro antigen presentation assay with LLO 91-99 -specific CD8 T cells. APC infected with Y. pseudotuberculosis strains pIB44(pHR430) and pIB102 (pHR430), which translocate hybrid YopE/LLO, were similarly recognized by LLO-specific CD8 T cells, whereas the hypertranslocating strain pIB155(pHR430) was recognized significantly better (data not shown). In the murine model of infection, we directly compared the influence of regular YopE/ LLO translocation mediated by an attenuated Y. pseudotuberculosis ypkA mutant strain with chimeric YopE hypertranslocation mediated by the yopK-null mutant strain on the efficiency of CD4 and CD8 T-cell priming. Mice immunized with pIB44(pHR430) or pIB155(pHR430) revealed no significant differences in the number of IFN-␥-producing T cells . Thus, it is important to point out that hypertranslocation per se is not a prerequisite for T-cell activation in vivo. However, it is also conceivable that hypertranslocation in contrast to regular translocation of an antigen might be advantageous in a situation when a certain critical threshold value of the cytosolic protein is needed for proper antigen processing and presentation.
To assess the influence of secreted versus translocated antigen display on antigen processing and T-cellular priming, we constructed two different plasmid-encoded hybrid YopE/LLO proteins. By engaging well-defined secretion and translocation domains of the type III molecule YopE (26, 45, 46, 54) fused to more than 300 amino acids of LLO, chimeric YopE was expressed in either secreted or translocated form. Biochemical fractionation of Yersinia-infected macrophage-like cells clearly revealed that YopE 1-138 /LLO encoded by pHR430 was translocated to the cytosol of host cells, whereas YopE 1-18 /LLO encoded by pHR429 lacking the translocation domain was efficiently secreted to the infection medium but was not detected in the Triton X-100-soluble P388D 1 cell lysate fraction. Western blot analysis of serial dilutions of the different bacterium-free infection medium fractions indicated that the amounts of secreted YopE 1-18 /LLO expressed by pIB102 (pHR429) and pIB155(pHR429) were approximately 25 times higher than the amounts of YopE 1-138 /LLO secreted by pIB102(pHR430) and pIB155(pHR430) (data not shown). Thus, we theoretically expected that the well-secreted version of chimeric YopE 1-18 /LLO could have the potential to enter the exogenous MHC class II-restricted antigen presentation pathway for proper CD4 T-cell priming. Strikingly, results from in vitro antigen presentation assays and also the enumeration of LLO-specific CD4 T cells from immunized mice indicated a superior efficacy of translocated over secreted LLO for MHC class II-restricted antigen processing and CD4 T-cell induction, respectively. We have to emphasize the fact that Yersinia-mediated translocation of a single hybrid protein results in simultaneous antigen-specific CD4 and CD8 T-cell priming. This desirable feature of a bacterial carrier vaccine appears to be specific for Yersinia. Our laboratory has previously demonstrated (46) that YopE 1-138 /LLO translocated by attenuated Salmonella results in MHC class I-restricted antigen presentation and efficient CD8 T-cell induction in mice. However, use of this construct did not induce any measurable MHC class II-restricted antigen presentation in vitro or CD4 T-cell responses in vivo (H. Rüssmann and G. Geginat, unpublished observations).
An important question arising from this study has to be addressed in future experiments. What is the underlying mechanism in Yersinia-infected APC that efficiently inhibits processing of secreted YopE/LLO via the exogenous MHC class II antigen presentation pathway? A better understanding of the Yersinia TTSS, which is crucial for the pathogenicity and the establishment of the extracellular ecological niche in lymphatic tissues, might contribute to elucidating some aspects of this question. The multicomponent TTSS of Yersinia is among the most complex protein secretion systems known. An essential part of such complexity and probably the most fascinating aspect of type III secretion is the fact that proteins are not only secreted from the bacterial cytoplasm but also delivered directly to the inside of the eukaryotic host cell, therefore effectively working as a "molecular syringe" (14, 30) . Four translocated Yop effector proteins are known to disturb the cytoskeleton dynamics and inhibit phagocytosis (18) . As mentioned earlier, YopE is a GTPase-activating protein that is active towards G proteins from the Rho family (4, 56) . The tyrosine phosphatase YopH (19) disturbs focal adhesion sites by dephosphorylating the focal adhesion kinase, p130
Cas , Fynbinding protein, paxillin, and SKAP-HOM (3, 5, 20, 37) . YopT, which is present in Y. enterocolitica but not in Y. pseudotuberculosis, modifies and inactivates RhoA (51, 58) , and the threonine kinase YopO (YpkA in Y. pseudotuberculosis) is activated by actin and binds to GTP-and GDP-bound forms of Rho GTPases (12, 27) . Does the concerted action of these antiphagocytic molecules also inhibit the uptake of secreted chimeric YopE/LLO and its subsequent endosomal MHC class II-restricted antigen processing? In our laboratory experiments are under way to answer this question.
The most interesting finding in this study is that translocation of antigen to the cytosol of APC rather than secretion of the same antigen results in enhanced CD4 T-cell activation. How do peptides derived from translocated YopE/LLO get associated with MHC class II molecules? Classically, APC are thought to present exogenous extracellular proteins on MHC class II to CD4 T cells and endogenous cytosolic proteins on MHC class I to CD8 T cells. Alternatively, it has been shown elsewhere that MHC class II can present peptides from cytosolic proteins (31). In fact, major peptides on MHC class II appear to be mainly from cellular rather than extracellular proteins (8, 43) . Although this could be explained in some cases by endolysosomal processing of membrane proteins, many of these peptides are from cytosol-resident proteins. We are currently investigating the mechanism of how translocated endogenous YopE/LLO is converted into peptides for loading on MHC class II molecules. Leupeptin and pepstatin A, both inhibitors of endosomal proteolysis, do not inhibit MHC class II antigen presentation of Yersinia-translocated LLO (data not shown), indicating that endolysosomal processing is not involved. However, to dissect this complicated pathway further experiments are needed.
Taking the data together, we demonstrate for the first time that an extracellular attenuated Y. pseudotuberculosis strain can be used for simultaneous antigen-specific CD4 and CD8 T-cell induction in orally vaccinated mice, resulting in protection against murine listeriosis. A novel finding of this study is that cytosolic delivery of LLO into APC by the yopK-null mutant strain led to efficient MHC class II presentation of the bacterial antigen. In the future, the mechanism of Yersinia type III-dependent translocation may become a useful tool for vaccination against intracellular pathogens which are controlled by both CD4 and CD8 T cells.
